Taiho Pharmaceuticals

View All

Duchenne-Muscular-Dystrophy-Pipeline-Insight
In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy

Sarepta Therapeutics, a leading player focused in developing precision genetic medicines for rare diseases with more than 25 programs ongoing, has recently announced the submission of New Drug Application (NDA) to the US FDA for Casimersen (SRP-4045) for the treatment of Duchenne muscular dystrophy (DMD) with a gen...

Find More